Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis

Molecular Neurobiology

Volumn 53, Issue 4, 2016, Pages 2733-2749

  Zhu, Mingqin ^a,e   Wang, Xiuzhe ^a,d   Hjorth, Erik ^a   Colas, Romain A ^b   Schroeder, Lisa ^a   Granholm, Ann Charlotte ^c   Serhan, Charles N ^b   Schultzberg, Marianne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Alzheimer; Human; Inflammation; Lipoxin; Maresin; Microglia; Neuroprotection; Omega 3; Resolvin; SPMs

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; LIPOXIN A; MARESIN 1; PRORESOLVING LIPID MEDIATOR; PROSTAGLANDIN D2; PROTECTIN D1; PROTECTIN DX; RESOLVIN D1; RESOLVIN D5; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); LIPID; PEPTIDE FRAGMENT; STAUROSPORINE;

ALZHEIMER DISEASE; ARTICLE; BRAIN NERVE CELL; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENTORHINAL CORTEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; LIQUID CHROMATOGRAPHY; MICROGLIA; NEUROPROTECTION; PHAGOCYTOSIS; PROTEIN FUNCTION; TANDEM MASS SPECTROMETRY; AGED; CHEMISTRY; DRUG EFFECTS; FEMALE; MALE; METABOLISM; NERVE CELL; PATHOLOGY; PHENOTYPE; POSTMORTEM CHANGE; TUMOR CELL LINE;

AGED; AMYLOID BETA-PEPTIDES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, LIQUID; ENTORHINAL CORTEX; FEMALE; HUMANS; LIPIDS; MALE; MICROGLIA; NEURONS; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; PHENOTYPE; POSTMORTEM CHANGES; STAUROSPORINE; TANDEM MASS SPECTROMETRY;

EID: 84949491620     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9544-0     Document Type: Article

References (87)

1. Farooqui AA, Wells K, Horrocks LA (1995) Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. Mol Chem Neuropathol 25(2–3):155–173
2. Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA (1996) Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer’s disease brain. Neurobiol Dis 3(1):51–63
3. Skinner ER, Watt C, Besson JA, Best PV (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer’s disease and control subjects. Brain 116(Pt 3):717–725
4. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115(10):2774–2783
5. Dullemeijer C, Durga J, Brouwer IA, van de Rest O, Kok FJ, Brummer RJ, van Boxtel MP, Verhoef P (2007) n-3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr 86(5):1479–1485
6. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST (2008) Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer’s disease. J Histochem Cytochem 56(12):1065–1073
7. Mohri I, Kadoyama K, Kanekiyo T, Sato Y, Kagitani-Shimono K, Saito Y, Suzuki K, Kudo T et al (2007) Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol 66(6):469–480
8. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D (2008) 5-Lipoxygenase gene disruption reduces Aβ pathology in a mouse model of Alzheimer’s disease. FASEB J 22(4):1169–1178
9. Cacabelos R, Alvarez XA, Fernandez-Novoa L, Franco A, Mangues R, Pellicer A, Nishimura T (1994) Brain interleukin-1β in Alzheimer’s disease and vascular dementia. Methods Find Exp Clin Pharmacol 16:141–151
10. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86(19):7611–7615
11. McGeer PL, Itagaki S, Tago H, McGeer EG (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79(1–2):195–200
12. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256(5054):184–185
13. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7(8):656–664
14. 42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons. PLoS One 5(12):e15600
15. Del Bo R, Angeretti N, Lucca E, De Simoni MG, Forloni G (1995) Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures. Neurosci Lett 188(1):70–74
16. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B (1999) TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J 13:63–68
17. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 47(2):425–432
18. Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510(7503):92–101
19. Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237(4819):1171–1176
20. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192(8):1197–1204
21. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278(17):14677–14687
22. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196(8):1025–1037
23. Buckley CD, Gilroy DW, Serhan CN (2014) Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40(3):315–327
24. Xu MX, Tan BC, Zhou W, Wei T, Lai WH, Tan JW, Dong JH (2013) Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses. CNS Neurosci Ther 19(4):235–243
25. Xu ZZ, Liu XJ, Berta T, Park CK, Lu N, Serhan CN, Ji RR (2013) NpD/PD1 protects against neuropathic pain in mice after nerve trauma. Ann Neurol 74(3):490–495
26. Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernandez-Lopez D, Pradillo JM, Caso JR, Vivancos J et al (2009) Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARγ-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 29(12):3875–3884
27. Cudaback E, Jorstad NL, Yang Y, Montine TJ, Keene CD (2014) Therapeutic implications of the prostaglandin pathway in Alzheimer’s disease. Biochem Pharmacol 88(4):565–572
28. Cunningham C, Skelly DT (2012) Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? J Neuroimmune Pharmacol 7(1):60–73
29. Wang X, Zhu M, Hjorth E, Cortés-Toro V, Eyjolfsdottir H, Graff C, Nennesmo I, Palmblad J et al (2015) Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement 11:40–50
30. Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, Mayeux R, Duff KE et al (2014) Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer’s disease. Nat Neurosci 17(2):304–311
31. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307(1):C39–C54
32. Dalli J, Serhan CN (2012) Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120(15):e60–e72
33. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, Gallego C, Comella JX (2000) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 75(3):991–1003
34. 42 by human microglia and decrease inflammatory markers. J Alzheimers Dis 35(4):697–713
35. Aisen PS, Davis KL (1994) Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psychiatry 151(8):1105–1113
36. Mann DM, Iwatsubo T, Fukumoto H, Ihara Y, Odaka A, Suzuki N (1995) Microglial cells and amyloid β protein (Aβ) deposition; association with Aβ40-containing plaques. Acta Neuropathol (Berl) 90(5):472–477
37. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B et al (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63(10):1402–1408
38. 42 and LPS in human microglia. J Alzheimers Dis 43:1237–1250
39. Haynes RL, van Leyen K (2013) 12/15-lipoxygenase expression is increased in oligodendrocytes and microglia of periventricular leukomalacia. Dev Neurosci 35(2–3):140–154
40. Lammers CH, Schweitzer P, Facchinetti P, Arrang JM, Madamba SG, Siggins GR, Piomelli D (1996) Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. J Neurochem 66(1):147–152
41. Ohtsuki T, Matsumoto M, Hayashi Y, Yamamoto K, Kitagawa K, Ogawa S, Yamamoto S, Kamada T (1995) Reperfusion induces 5-lipoxygenase translocation and leukotriene C4 production in ischemic brain. Am J Physiol 268(3 Pt 2):H1249–H1257
42. Pratico D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA, Trojanowski JQ, Lee VM (2004) 12/15-lipoxygenase is increased in Alzheimer’s disease: possible involvement in brain oxidative stress. Am J Pathol 164(5):1655–1662
43. Luo M, Jones SM, Phare SM, Coffey MJ, Peters-Golden M, Brock TG (2004) Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 279(40):41512–41520
44. 4 production. J Immunol 181(5):3515–3523
45. De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L (2005) Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2(1):4
46. Bazinet RP, Laye S (2014) Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 15(12):771–785
47. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, Cotman CW, Piomelli D (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One 5(9):e12538
48. Medeiros R, Kitazawa M, Passos GF, Baglietto-Vargas D, Cheng D, Cribbs DH, LaFerla FM (2013) Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol 182(5):1780–1789
49. Mizwicki MT, Liu G, Fiala M, Magpantay L, Sayre J, Siani A, Mahanian M, Weitzman R et al (2013) 1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer’s disease patients. J Alzheimers Dis 34:155–170
50. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG (2011) Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR-γ-mediated mechanisms in Alzheimer’s disease models. PLoS ONE 6(1):e15816
51. 4 receptor. J Biol Chem 272(11):6972–6978
52. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 107(4):1660–1665
53. Deshmukh M, Johnson EM Jr (2000) Staurosporine-induced neuronal death: multiple mechanisms and methodological implications. Cell Death Differ 7(3):250–261
54. Padurariu M, Ciobica A, Lefter R, Serban IL, Stefanescu C, Chirita R (2013) The oxidative stress hypothesis in Alzheimer’s disease. Psychiatr Danub 25(4):401–409
55. Prieto P, Cuenca J, Traves PG, Fernandez-Velasco M, Martin-Sanz P, Bosca L (2010) Lipoxin A4 impairment of apoptotic signaling in macrophages: implication of the PI3K/Akt and the ERK/Nrf-2 defense pathways. Cell Death Differ 17(7):1179–1188
56. Calandria JM, Asatryan A, Balaszczuk V, Knott EJ, Jun BK, Mukherjee PK, Belayev L, Bazan NG (2015) NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival. Cell Death Differ 22(8):1363–1377
57. Calandria JM, Mukherjee PK, de Rivero Vaccari JC, Zhu M, Petasis NA, Bazan NG (2012) Ataxin-1 poly(Q)-induced proteotoxic stress and apoptosis are attenuated in neural cells by docosahexaenoic acid-derived neuroprotectin D1. J Biol Chem 287(28):23726–23739
58. Balas L, Guichardant M, Durand T, Lagarde M (2014) Confusion between protectin D1 (PD1) and its isomer protectin DX (PDX). An overview on the dihydroxy-docosatrienes described to date. Biochimie 99:1–7
59. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, Yang R, Colgan SP et al (2006) Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 176(3):1848–1859
60. Liu M, Boussetta T, Makni-Maalej K, Fay M, Driss F, El-Benna J, Lagarde M, Guichardant M (2014) Protectin DX, a double lipoxygenase product of DHA, inhibits both ROS production in human neutrophils and cyclooxygenase activities. Lipids 49(1):49–57
61. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG (2004) Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A 101(22):8491–8496
62. Antony R, Lukiw WJ, Bazan NG (2010) Neuroprotectin D1 induces dephosphorylation of Bcl-xL in a PP2A-dependent manner during oxidative stress and promotes retinal pigment epithelial cell survival. J Biol Chem 285(24):18301–18308
63. Halapin NA, Bazan NG (2010) NPD1 induction of retinal pigment epithelial cell survival involves PI3K/Akt phosphorylation signaling. Neurochem Res 35(12):1944–1947
64. Weinberger B, Quizon C, Vetrano AM, Archer F, Laskin JD, Laskin DL (2008) Mechanisms mediating reduced responsiveness of neonatal neutrophils to lipoxin A4. Pediatr Res 64(4):393–398
65. Liao Z, Dong J, Wu W, Yang T, Wang T, Guo L, Chen L, Xu D et al (2012) Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway. Respir Res 13:110
66. Kovacs DM, Mancini R, Henderson J, Na SJ, Schmidt SD, Kim TW, Tanzi RE (1999) Staurosporine-induced activation of caspase-3 is potentiated by presenilin 1 familial Alzheimer’s disease mutations in human neuroglioma cells. J Neurochem 73(6):2278–2285
67. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA et al (1999) Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science 286(5448):2352–2355
68. Townsend KP, Shytle DR, Bai Y, San N, Zeng J, Freeman M, Mori T, Fernandez F et al (2004) Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci Res 78(2):167–176
69. Togo T, Akiyama H, Kondo H, Ikeda K, Kato M, Iseki E, Kosaka K (2000) Expression of CD40 in the brain of Alzheimer’s disease and other neurological diseases. Brain Res 885(1):117–121
70. Ke ZJ, Calingasan NY, DeGiorgio LA, Volpe BT, Gibson GE (2005) CD40-CD40L interactions promote neuronal death in a model of neurodegeneration due to mild impairment of oxidative metabolism. Neurochem Int 47(3):204–215
71. Volmar CH, Ait-Ghezala G, Frieling J, Weeks OI, Mullan MJ (2009) CD40/CD40L interaction induces Aβ production and increases γ-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Exp Cell Res 315(13):2265–2274
72. 2 integrins. J Neuroimmunol 30(1):81–93
73. Barthel SR, Jarjour NN, Mosher DF, Johansson MW (2006) Dissection of the hyperadhesive phenotype of airway eosinophils in asthma. Am J Respir Cell Mol Biol 35(3):378–386
74. Pillay J, Ramakers BP, Kamp VM, Loi AL, Lam SW, Hietbrink F, Leenen LP, Tool AT et al (2010) Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia. J Leukoc Biol 88(1):211–220
75. Wilson RP, Winter SE, Spees AM, Winter MG, Nishimori JH, Sanchez JF, Nuccio SP, Crawford RW et al (2011) The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi. Infect Immun 79(2):830–837
76. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM et al (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278(44):43807–43817
77. Luo CL, Li QQ, Chen XP, Zhang XM, Li LL, Li BX, Zhao ZQ, Tao LY (2013) Lipoxin A4 attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury. Brain Res 1502:1–10
78. Li Y, Dalli J, Chiang N, Baron RM, Quintana C, Serhan CN (2013) Plasticity of leukocytic exudates in resolving acute inflammation is regulated by microRNA and proresolving mediators. Immunity 39(5):885–898
79. Woster AP, Combs CK (2007) Differential ability of a thiazolidinedione PPARγ agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells. J Neurochem 103(1):67–76
80. Xu J, Barger SW, Drew PD (2008) The PPAR-γ agonist 15-deoxy-δ-prostaglandin J(2) attenuates microglial production of IL-12 family cytokines: potential relevance to Alzheimer’s disease. PPAR Res 2008:349185
81. Xu J, Storer PD, Chavis JA, Racke MK, Drew PD (2005) Agonists for the peroxisome proliferator-activated receptor-α and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res 81(3):403–411
82. Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM (2012) Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. PLoS One 7(11):e50976
83. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH et al (2013) Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid β. Neuron 78(4):631–643
84. Aronoff DM, Serezani CH, Carstens JK, Marshall T, Gangireddy SR, Peters-Golden M, Reddy RC (2007) Stimulatory effects of peroxisome proliferator-activated receptor-γ on Fcγ receptor-mediated phagocytosis by alveolar macrophages. PPAR Res 2007:52546
85. Majai G, Sarang Z, Csomos K, Zahuczky G, Fesus L (2007) PPAR-γ-dependent regulation of human macrophages in phagocytosis of apoptotic cells. Eur J Immunol 37(5):1343–1354
86. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT (2012) PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 32(48):17321–17331
87. Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, Petasis NA, Serhan CN (2013) The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J 27(7):2573–2583